Oncology

A type of signalling molecule called filamin A may play a key role in the battle against triple-negative breast cancer. This research could lead to more personalized and effective treatments by targeting the unique ways filamin A influences cancer growth and spread, offering new hope for those affected by this type of cancer, which is...

Key Takeaways A new stool test that looks for signs of colon cancer was found to be more accurate than the existing test Nearly 2 million people a year are diagnosed with colon cancer, which is curable if detected early Developers say the new test is as easy to use as the current one Dutch...

Significant improvement seen in overall survival with pembrolizumab versus placebo and across key subgroups For patients with clear-cell renal cell carcinoma (ccRCC), overall survival (OS) is improved for those receiving pembrolizumab versus placebo at a median follow-up of about 57 months, according to a study presented at the American Society of Clinical Oncology annual Genitourinary...

The spatial distribution of CD103+CD8+ tissue-resident memory T cells is a prognostic biomarker for non-small cell lung cancer, according to the results of a recent cohort study. Tissue-resident memory T cells (TRM) are a special population of immune cells that reside in solid[spacer height=”10px”]tumors and their microenvironment. Although emerging evidence has linked these cells to[spacer...

Serum levels of 8-hydroxy-deoxyguanosine were positively correlated with ionizing radiation in non-small cell lung cancer, with possible prognostic significance in the squamous pathology subgroup in an observational study. Ionizing radiation is associated with DNA damage, which can be direct or indirect, as with the production of reactive oxygen species (ROS). The most common ROS-induced base...

The long non-coding RNA LINC02159 promotes non-small cell lung cancer progression through ALYREF/YAP1 signaling, according to the results of a recent cell culture study. Lung cancer is the leading cause of cancer-related deaths globally. Long non-coding RNAs (lncRNAs) have recently emerged as key regulators in cancer development and progression, including non-small cell lung cancer (NSCLC),...

Amivantamab plus lazertinib shows durable clinical activity in osimertinib-relapsed, epidermal growth factor receptor-mutated advanced non-small cell lung cancer in a phase I study. Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), is the current standard-of-care treatment for EGFR-mutated non-small cell lung cancer (NSCLC). However, resistance is common, and there are no...

Circulating tumor DNA response to pembrolizumab can identify patients with molecular disease progression needing treatment intensification, according to the results of a phase II/III clinical trial. Circulating tumor DNA (ctDNA) has demonstrated promise in identifying primary resistance to immunotherapy. Concerning non-small cell lung cancer (NSCLC), where pembrolizumab and combination pembrolizumab–carboplatin–taxane/pemetrexed are the first-line options, it...

A recent literature review identifies promising therapeutic agents that have shifted the non-small cell lung cancer treatment paradigm. Lung cancer is the leading cause of cancer mortality worldwide. Research is rapidly evolving regarding the treatment of non-small cell lung cancer (NSCLC) with biomarker-driven targeted therapy and immunotherapy using checkpoint inhibitors.  A review of phase III...